871239-62-2Relevant academic research and scientific papers
Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron Microscopy
Terrett, Jack A.,Chen, Huifen,Shore, Daniel G.,Villemure, Elisia,Larouche-Gauthier, Robin,Déry, Martin,Beaumier, Francis,Constantineau-Forget, Léa,Grand-Ma?tre, Chantal,Lépissier, Luce,Ciblat, Stéphane,Sturino, Claudio,Chen, Yong,Hu, Baihua,Lu, Aijun,Wang, Yunli,Cridland, Andrew P.,Ward, Stuart I.,Hackos, David H.,Reese, Rebecca M.,Shields, Shannon D.,Chen, Jun,Balestrini, Alessia,Riol-Blanco, Lorena,Lee, Wyne P.,Liu, John,Suto, Eric,Wu, Xiumin,Zhang, Juan,Ly, Justin Q.,La, Hank,Johnson, Kevin,Baumgardner, Matt,Chou, Kang-Jye,Rohou, Alexis,Rougé, Lionel,Safina, Brian S.,Magnuson, Steven,Volgraf, Matthew
, p. 3843 - 3869 (2021/05/04)
Transient receptor potential ankyrin 1 (TRPA1) is a nonselective calcium-permeable ion channel highly expressed in the primary sensory neurons functioning as a polymodal sensor for exogenous and endogenous stimuli and has generated widespread interest as a target for inhibition due to its implication in neuropathic pain and respiratory disease. Herein, we describe the optimization of a series of potent, selective, and orally bioavailable TRPA1 small molecule antagonists, leading to the discovery of a novel tetrahydrofuran-based linker. Given the balance of physicochemical properties and strong in vivo target engagement in a rat AITC-induced pain assay, compound 20 was progressed into a guinea pig ovalbumin asthma model where it exhibited significant dose-dependent reduction of inflammatory response. Furthermore, the structure of the TRPA1 channel bound to compound 21 was determined via cryogenic electron microscopy to a resolution of 3 ?, revealing the binding site and mechanism of action for this class of antagonists.
3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF
-
, (2021/11/13)
The present invention provides KDM5 inhibitor. The compound disclosed herein represented by the general formula (I) : wherein all symbols have the same meanings as the definitions described in the specification; or a salt thereof is useful as a prophylact
OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
-
, (2018/09/28)
The invention relates to compounds of formula I: (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositio
Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: Development of a potent and CNS penetrant [3.1.0]-based lead
Jones, Carrie K.,Sheffler, Douglas J.,Williams, Richard,Jadhav, Sataya B.,Felts, Andrew S.,Morrison, Ryan D.,Niswender, Colleen M.,Daniels, J. Scott,Conn, P. Jeffrey,Lindsley, Craig W.
, p. 1067 - 1070 (2014/03/21)
This Letter describes the development and SAR of a novel series of GlyT1 inhibitors derived from a scaffold hopping approach that provided a robust intellectual property position, in lieu of a traditional, expensive HTS campaign. Members within this new [3.1.0]-based series displayed excellent GlyT1 potency, selectivity, free fraction, CNS penetration and efficacy in a preclinical model of schizophrenia (prepulse inhibition).
